Pharmaceutical

Payton Nyquvest Founder and Chief Executive Officer, Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) and his team joined Michael Kousaie Vice-President, Strategy and Product Innovation, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.


Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, they are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com .

For Market Openings: Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact avservices@tmx.com . The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET

Date: Thursday, December 16, 2021

Time: 9:00am - 9:30am

Place:  120 Adelaide Street, W

SOURCE Toronto Stock Exchange

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/16/c6076.html

News Provided by Canada Newswire via QuoteMedia

NUMI:CA
Numinus to expand state-of-the-art psychedelics research laboratory

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services,
accelerates IP development and increases psychedelic supply capacity

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf's Grassroots Brand and Ganjier Announce First-of-its-Kind Cannabis Education Partnership

Pilot Program for Passionate Team Members and Partners Solidifies Curaleaf's Dedication to Advancing the Cannabis Movement

- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), today announced a first-of-its-kind cannabis education partnership for its Grassroots brand with Ganjier, the Cannabis Sommelier Certification Program.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Supports Disabled American Veterans Job Fair Through National Partnership

Company to discuss career opportunities for veterans at recruiting event in Atlanta on Dec. 8

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., is proud to support the Disabled American Veterans (DAV) at its RecruitMilitary Job Fair. Held in Atlanta, Ga. on Thursday, December 8 Trulieve's talent acquisition team will meet with U.S. veterans, military spouses, transitioning military and members of the Guard and Reserve.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Unveils its New CBC Product: Spinach FEELZ Day Trip Gummies With THC+CBC

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, today announced the launch of a CBC-focused product, the Spinach FEELZ™ THC+CBC Day Trip Mango Lime gummies, utilizing Ginkgo Bioworks' platform for organism design and development.

The Spinach FEELZ™ Day Trip gummies are the first CBC gummy product in Canada and the first of its kind to feature a 3:1 ratio of CBC to THC. The product is currently available in Alberta and British Columbia and will be rolled out to additional provinces over the coming weeks:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

TerrAscend Announces Upcoming Conference Participation

TerrAscend Corp. ("TerrAscend" or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that its executive team will participate in the following virtual conferences on December 7, 2022 :

Cowen's 5th Annual Cannabis Conference, December 7, 2022 : Ziad Ghanem, President and Chief Operating Officer, will participate in an MSO Group panel discussion on Wednesday, December 7, 2022 , at 12:30 PM ET , and management will also host a series of one-on-one meetings throughout the day. For more information, please contact your Cowen representative.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings Celebrates the Life and Legacy of Dr. Jay Westwater with Special Event

Event commemorated Dr. Westwater's life with updates on new research into cannabis and cancer –

– New "Dr. Westwater" brand of topical cannabis products unveiled at the event –

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Trulieve Launches Khalifa Kush Cannabis in Pennsylvania Through Exclusive Partnership with Wiz Khalifa

Wiz Khalifa to meet patients at two Trulieve branded dispensaries on December 12 ;
Pop-up launch events held at select Trulieve branded dispensaries statewide

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the official launch of Khalifa Kush premium medical marijuana products statewide in all Trulieve Branded Pennsylvania retail locations starting Monday, December 12, 2022 . This is an exclusive partnership with multi-platinum selling, GRAMMY® and Golden Globe® Award-nominated recording artist Wiz Khalifa.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×